A Randomized Phase III Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer

Diseases and Conditions Researched


What is the purpose of this trial?

This Phase III study has been designed to confirm that adding custirsen ;to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter, international trial. Treatment will consist of cabazitaxel/prednisone/custirsen ;vs. cabazitaxel/prednisone.

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Oncogenex
Last Updated:
Study HIC#: 1302011537